Current guidelines in peritoneal dialysis – Part II

Ana Carina Ferreira1-2, Andreia Borges3,4, Cristina Pinto Abreu5, Fernando Teixeira e Costa6, Marta Pereira5, Rui Castro7, Sara Barreto6, on Behalf of the Peritoneal Dialysis’ Study Group of the Portuguese Society of Nephrology (annex 1)

1 Department of Nephrology of Curry Cabral Hospital – Centro Hospitalar e Universitário de Lisboa Central, Lisbon, Portugal
2 Nova Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal
3 Department of Nephrology, Centro Hospital Universitário de Coimbra, Coimbra, Portugal
4 University Clinic of Nephrology, Faculty of Medicine, Universidade de Coimbra, Coimbra, Portugal
5 Department of Nephrology of Centro Hospitalar de Lisboa Norte, Lisbon, Portugal
6 Department of Nephrology of Hospital Gracia de Orta, Almada, Portugal
7 Department of Nephrology of Centro Hospitalar de Trás-os-Montes e Alto Douro, Vila Real, Portugal

ABSTRACT
A successful peritoneal dialysis program depends on knowledge of the current recommendations and on evidence-based practice guidelines. In this second article, we review the dialysis prescription and the nutritional and cardiovascular management of peritoneal dialysis patients in the light of the existing guidelines advocated by different international societies.

INTRODUCTION
Peritoneal dialysis (PD) is a well-established dialysis technique used to treat uremic patients since 1970s. Although underused, this modality has many advantages, namely preservation of renal residual function (RRF), hemodynamic stability, the maintenance of quality of life and cost savings1, among others. A successful PD program is dependent on many variables, and a good training of both physicians and PD nurses is essential. Also, the knowledge of current recommendations, centered on evidence-based practice guidance is of extreme importance.

This is part II of a review article about the current existing guidelines in adult patients and focuses on dialysis prescription and metabolic and cardiovascular management and nutrition. Part I reviewed the current guidelines on catheter insertion and catheter-related infections. For the purpose of these two articles, we looked at the International Society of Peritoneal Dialysis (ISPD) guidelines, the UK Renal Association guidelines, European Renal Best Practices (ERBP), Kidney Disease Improving Global Outcomes (KDIGO), and the Portuguese Good Practice Manual in Chronic Dialysis.

CURRENT GUIDELINES ON PERITONEAL DIALYSIS

Guidelines on Efficacy – fluids and solutes removal

1. Fluid removal and regulation of volume

Fluid overload in PD patients is often multifactorial. Fluid status is a balance between fluid output (UF and/or diuresis) and fluid input (fluid and salt intake). So, despite good UF and residual diuresis, patients still can have fluid overload, stressing the important role of dietary restriction of salt and fluid intake. Adherence to a sodium-restricted diet is critical, and dietary education should be a part of each patient’s care plan.

The discrepancy between ultrafiltration and fluid overload makes it very difficult to formulate UF targets in guidelines for adequacy of
PD. Nevertheless this has been tried. The ISPD defines UF failure (UFF) as net UF less than 400 ml after a dwell of 4 h with 4% glucose based dialysis solution (3x4 definition). This definition is useful because it distinguishes peritoneal UF failure from fluid overload16.

In patients with RRF, it is difficult to set a fixed UF volume. In these patients, maintaining a clinical state without edema, hypertension and cardiac overload is most important than achieving a particular level of UF volume. The ISPD guideline on targets for solute and fluid removal in adult patients on chronic peritoneal dialysis does not include specific suggestions other than the statement “Attention should be paid to both urine volume and the amount of UF, with the goal of maintaining euvolemia”17.

Other societies have provided further recommendations. The Committee of European Best Practice Guidelines decided to formulate targets based on those achieved by dialysis only: “these targets should be adequate for anuric PD patients; the presence of RRF compensate in situations where the peritoneal targets are not achieved”. They decided on an arbitrary target of 1L/day for net UF in anuric patients18. The Canadian Society of Nephrology Clinical Practice Guidelines and Recommendations on PD adequacy19 suggests that a low net daily peritoneal UF volume (< 750 ml in anuric or <250 ml in patients with RRF) be an indication for careful evaluation of volume status (looking for evidence of fluid overload) and of dietary fluid and fluid intake (looking for evidence of insufficient intake or malnutrition). The Renal Association Clinical Practice Guideline on PD in adults and children20 recommend that anuric patients who consistently achieve a daily UF of less than 750 ml should be closely monitored.

One note of importance is the potential impact of bag overfills on the overestimation of UF and fluid overload21. It can be that the overestimation of real UF by neglecting overfill can lead to overhydration, as it gives the patient and physician the false feeling of adequate UF.

3. Assessment of peritoneal membrane function

The functional assessment of the peritoneal membrane, specifically solute transport rate and ultrafiltration capacity, provides useful information on the correct prescription of the peritoneal dialysis regimen and it makes it possible to monitor changes in peritoneal membrane over time.

The majority of guidelines18-20,27-30 recommended performing a baseline peritoneal kinetic analysis 4–8 weeks and no more than 3 months after starting PD in order to provide another useful tool in the process of prescribing an adequate dialysis regimen and to evaluate the initial characteristics of the peritoneum. No clear consensus exists for repeating the evaluation at different points. Some guidelines27 recommended not repeating the PET at preset intervals, rather to repeat the test when clinical problems arise. Other guidelines16 suggest performing the evaluation at least once a year and whenever clinically indicated.

We think that peritoneal kinetics must be performed every year as a standard practice and/or when clinical problems arise such as volume overload or insufficient dialysis and following cases of peritonitis, above all if the episode is aggressive (1 month after resolution) or if a decrease in UF is detected. In addition, a recent PET test should be available before the change from CAPD to APD. Frequent mistakes are made in prescribing APD without knowledge of membrane small solute transport rate or water removal capacity. Slow transporters are better managed with CAPD while fast transporters are better managed with APD. The concept of “adapted PD” indeed focuses on membrane physiology towards a better prescription. Without a previous PET test, dwell times and volumes might be wrongly prescribed. The measurement of intraperitoneal pressure is a tool that can also help individualize intraperitoneal volume prescription in order to optimize adequacy while avoiding counteracting UF or promoting hernias.
There is insufficient evidence to prefer one test of peritoneal membrane characteristic to another for clinical prescription\textsuperscript{32}. We prefer modified PET (3.86\% instead 2.27\%) with temporary drainage after 1 hour for weighing and sampling, followed by reinfusion and final drainage after 4 hours for several orders of reasons:

- This methodology is recommended by the ISPD in order to define UF failure (<400 ml) and to obtain standardized measure of UF;
- The peritoneal membrane’s UF capacity is easier to quantify because of the higher quantity of UF that can be obtained; the coefficient of variation of UF has been quantified at approximately 50\% for the 2.27\% PET and < 10 \% for the 3.86\% PET\textsuperscript{31};
- The sodium sieving value at 60 minutes allows for the examination of aquaporin function;
- The results obtained in terms of D/P creatinine ratios are compared to those obtained using a PET 2.27\% which allows the continued classification of patients based on their capacity for small molecules transport;
- Is better at differentiating between small pore UF and free water transport (UF across the aquaporin-1 channels).

Reduced or absent free water transport may contribute to reduced UF capacity or UF failure, as it represents approximately 50\% of peritoneal UF in the first part of an exchange with a hypertonic solution. The loss of free water transport and the osmotic conductance to glucose should suggest severe alterations in peritoneal membrane\textsuperscript{32}.

The double mini-PET measures the osmotic conductance to glucose i.e., the capacity to generate UF with the osmotic stimulus of glucose that is more or less hypertonic. It indicates the amount of UF that can be obtained by increasing of glucose in PD solution. Indeed osmotic conductance measures the capacity to generate UF by both pores and, therefore, a reduction indicates a decrease in the peritoneum’s overall capacity to generate UF\textsuperscript{33}. In cases of UF, the double mini-PET provides additional indications for the prescription of the most suitable PD mode.

4. Avoidance of routine utilization of hypertonic glucose solutions

Peritoneal dialysis UF becomes increasingly important as RRF declines and can be modified by adjusting the type of PD solutions use. Increasing the strength of glucose solution can enhance UF volume by increasing the osmotic gradient. However, there is the risk of enhanced fluid intake, not only because of hyperglycemia associated with poor glycemic control, but also because of hypernatremia associated with sodium sieving enhances thirst. The regular use of hypertonic glucose dialysis fluid is associated with systemic effects such as weight gain\textsuperscript{34}, poor diabetic control, delayed gastric emptying\textsuperscript{35} and furthermore it is associated with a more rapid deterioration of peritoneal membrane function\textsuperscript{36,37}.

As RRF decreases, icodextrin can and should be added to enhance UF volume. The removed volume using icodextrin will also eliminate more sodium than the same UF volume when using glucose based solutions. Compared with the use of 4.25\% glucose, use of icodextrin increases UF volumes in long duration dwells\textsuperscript{38,39} and leads to a sustained reduction in extracellular fluid volume\textsuperscript{40,41}. In the Cochrane review by Cho et al, prescription of icodextrin was associated with improved peritoneal UF and mitigated uncontrolled fluid overload\textsuperscript{42}.

Icodextrin is recommended for dwells longer than 8h such as in the day dwell APD and the overnight dwell in CAPD. There is preliminary evidence that twice daily icodextrin may be safe and may enhance UF in patients with evidence of UFF\textsuperscript{43,44}.

5. Adaptation of PD protocols to the peritoneal membrane transport

The concept that fast transport status is linked to overhydration is well established in the minds of many\textsuperscript{45-47}. A meta-analysis\textsuperscript{48} of a number of prospective observational studies confirmed a worse prognosis (particularly in terms of survival) for high transporters than for patients with lower or slower transport characteristics. The same study demonstrated that treatment with APD, in a subgroup of patients, made the peritoneal transport characteristic non-influential in terms of patient survival. It is, then, important to keep the message that selective APD prescription, particularly taking into account peritoneal membrane transport status, has changed the outcome of fast transporters. A fast transporter status is no longer a threat if adequately managed with updated prescription.

Fast transporters have a rapid dissipation of their glucose gradient, and thus negative UF during longer dwells. Therefore, for fast transporters, short dwells are recommended\textsuperscript{29}, and APD with its short dwells might lead to better outcomes for these patients\textsuperscript{49}. Some authors\textsuperscript{50} have reported that with the advent of APD and icodextrin, the mortality of fast transporters, which in the past was much higher than for other transporter types, has become similar to that of patients belonging to other transporter categories. The use of icodextrin for the long exchange will prevent fluid reabsorption.

For slow transporters, manual CAPD is indicated, with high single exchange volumes\textsuperscript{29}. Too short dwells can induce sodium sieving in slow transporters and thus lead to removal of free water but not of sodium, resulting in fluid retention\textsuperscript{51,52}. But if APD is performed with a low number of cycles, avoiding too short dwell times and sodium sieving, there are no differences in sodium removal or volume control between APD and CAPD.

6. Preservation of RRF

As mentioned above, RRF is one of the most important factors that predict survival in PD patients and also helps maintain extracellular volume.

The EURO-BCM study showed that there is a tendency toward development of overhydration in patients with reduced renal diuresis\textsuperscript{6}. Similarly in the study by Konings et al\textsuperscript{53} a statistically significant relationship between state of hydration and RRF was found: PD patients with RRF less than 2 ml/min had increased levels of extracellular fluid compared with those who had better preserved residual GFR. Unfortunately, RRF declines during treatment by PD. Longitudinal studies have shown that RRF declines progressively with time on dialysis. In general, most PD patients will have lost their RRF within 3-5 years after the start of their treatment\textsuperscript{24}. In the CANUSA study\textsuperscript{31}, RRF decreased from 3.8 to 1.4 ml/ min over a mean follow-up period of 2 years.

Preservation of RRF plays a central role for achieving adequacy of dialysis. Adequate strategies to preserve RRF should be pursued. These
include the use of ACEi, ARBs, diuretics, and avoidance of nephrotoxic drugs and hypovolemia. ACE inhibitors (ramipril 5 mg) and ARBs (val- satan) have been reported in two RCT to be effective for the preservation of RRF in patients undergoing PD.55,56. Recently, Zhang et al57 systemically reviewed the effect of ACEi and ARB in preserving RRF in PD patients, and found that blocking the renin-angiotensin-aldosterone system (RAAS) with ACEi or ARBs may halt the decline in RRF in PD patients.

The use of high dose diuretics in individuals with RRF is supported by a RCT conducted in incident CAPD patients who received either furosemide 250 mg daily (plus metazolene 5 mg daily if diuresis was less than 500 ml in 24h) or no diuretics and were followed for 12 months. Patients treated with diuretics experienced an increase in urine output and urinary sodium excretion with no difference in the rate of loss of RRF compared with the control group58.

The greatest challenge in the management of PD patients consists of removing the correct amount of fluid, avoiding both fluid excess and fluid depletion. It has been argued that patients should be kept slightly overhydrated to preserve RRF because this has been associated with improved outcomes. However, retrospective observational data seem to indicate that an increased ECW/TBW ratio is not associated with improved outcomes.59,60. Episodes of volume depletion are associated with increased risk of loss in RRF61. Dehydration can cause acute kidney injury (AKI) and loss of RRF; this may be attributed to the functional reductions of aquaporins, renal vasoconstriction and structural changes in tubular system in the condition of hypovolemia62. Differing results have been found regarding the use of aminoglycosides and their effect on RRF63,64. When alternative acceptable antibiotics are available, ami- noglycosides should be avoided in the setting of preserved RRF. Avoid- ance of other nephrotoxic drugs such as non-steroidal anti-inflamma- tory medications and intravenous contrast dye may also be beneficial in preserving RRF65,66.

Traditional PD solutions are rich in glucose degradation products (GDPs), which have been demonstrated to be associated with higher serum levels of advanced glycation end products and progressive renal injury67. Modifying the peritoneal dialysate by raising pH, reducing glucose, and using non-lactate fluids as a buffer was thought to lessen the adverse effects of conventional PD solutions. Previous small, ran- domized controlled trials (RCTs) have demonstrated conflicting results with respect to the effects of biocompatible PD solutions on RRF decline in PD patients compared with conventional PD solutions68-72. Yohanna et al73 systematically reviewed 11 trials in which 643 patients were included. They reported that the use of a neutral-pH, low-GDP PD solutions resulted in better preserved RRF after various study periods. Yohanna et al73 systematically reviewed 11 trials in which 643 patients were included. They reported that the use of a neutral-pH, low-GDP PD solutions resulted in better preserved RRF after various study periods.59,60.

In the balANZ trial, the largest and highest quality RCT of biocompat- ible solutions examining RRF published to date, the primary unadjusted analysis found a non-significant (p = 0.06) difference in RRF decline between the intervention and control groups across the first and sec- ond 12 months of the study. Nonetheless, the biocompatible group did experience a significantly lower hazard of anuria (hazard ratio [HR] 0.36; 95% confidence interval [CI], 0.13 – 0.96)74. In the secondary analysis of the balANZ trial75, after adjusting for a range of demo- graphic, clinical and dialysis characteristics, the use of biocompatible PD solution was associated with 27% better preservation of RRF (p = 0.004) and 37% better preservation of residual urine volume (p < 0.001) compared with the use of conventional PD solution. These findings are in keeping with the consistent findings of systematic reviews and meta-analyses of RCTs those biocompatible PD solutions better preserve RRF and residual urine volume compared with conven- tional solutions42,73,76,77. The results of this study therefore further support these systematic reviews and the recommendations of the International Society for Peritoneal Dialysis (ISPD) guidelines that neutral pH, low glucose degradation product PD solutions should be used for better preservation of RRF78.

### Solute removal

Solute removal guidelines for peritoneal dialysis (PD) clinicians are comparable to a beacon for a sailor. To reach optimal results, they need a sense of orientation regarding their objectives, well being of their patients and reaching their seaport, respectively.

We reviewed the ISPD guidelines17, the UK Renal Association guide- lines (RA)20, ERBP18, KDOQI79, Canadian Society of Nephrology (CSN) Guidelines/Recommendations19 and also the Portuguese Good Prac- tice Manual (PGPM) in Chronic Dialysis solutes clearance recommen- dations80 (Table 1).

The weekly Kt/V is a standard index of PD solute removal. Several guidelines reinforce it as a reproducible and practical method to reach adequate dialysis dose for PD patients. Nevertheless, some authors disputed this consensus, with reasonable scientific basis, and pre- sented new solute clearance markers, like the Wang L. dialysis index (DI), which includes the dietary intake in the clearance rate81.

The calculation of V (volume) is a significant drawback for total weekly Kt/V interpretation in PD. For instances, underweight and overweight patients should have their V calculated with their ideal body weight, according to the ISPD Guidelines/Recommendations17. Debowska and colleagues has also proposed Kt as a potential auxiliary index in PD, as Kt/V depends strongly on body size82. Currently in clinical practice, however, V is estimated from the Watson or Hume equation in adults79.

All the guidelines propose a weekly total (urinary + peritoneal) Kt/V of 1.7 as a minimum target (grade A), as expressed in Table 1.

### Table 1

<table>
<thead>
<tr>
<th>Guidelines</th>
<th>Weekly total Kt/V</th>
<th>Creatinine clearance</th>
</tr>
</thead>
<tbody>
<tr>
<td>ERBP – 2005</td>
<td>≥1.7A</td>
<td>≥45 liters/week/1.73m²C*</td>
</tr>
<tr>
<td>KDOQI – 2006</td>
<td>≥1.7A</td>
<td>–</td>
</tr>
<tr>
<td>ISPD – 2006</td>
<td>≥1.7A</td>
<td>≥45 liters/week/1.73m² (APD) C</td>
</tr>
<tr>
<td>CSN – 2011</td>
<td>≥1.7C</td>
<td>–</td>
</tr>
<tr>
<td>RA – 2017</td>
<td>≥1.7A</td>
<td>≥50 liters/week/1.73m²A</td>
</tr>
</tbody>
</table>

Levels of evidence A, B or C

* APD or Low-Transporters
The ADEMEX\textsuperscript{10} and the Hong Kong\textsuperscript{83} randomized controlled trials found no improvement in patient survival with peritoneal \( \text{Kt/V} \) above 1.7. So, in anuric patients peritoneal \( \text{Kt/V} \) should be greater than 1.7.

It is important to note that both RA and ISPD guidelines recommend increasing dialysis dose for patients experiencing uremic symptoms, even if they accomplish the minimum clearance targets (grade 1B)\textsuperscript{17,20}. The discrepancy between small and larger molecules clearance leads the same guidelines to propose another recommendation, in favour of continuous regimens particularly in anuric patients (grade 1B)\textsuperscript{17,20}.

The other solute removal index currently being used in PD practice is weekly creatinine clearance, adjusted to 1.73m\textsuperscript{2}. The caveat of this method relates to the major impact of peritoneal membrane transport characteristics in creatinine clearance. Although the ISPD workgroup stated it was a superfluous to use creatinine clearance, the guidelines/recommendations recommended an additional target of 45 L/week/1.73m\textsuperscript{2} in APD (grade C)\textsuperscript{17}.

The current clearance targets (weekly \( \text{Kt/V} \) and creatinine clearance) are attainable with easiness, particularly if the patients maintain significant residual renal function and/or are using Automated Peritoneal Dialysis. Conversely, if the targets are not achieved, patients should be monitored carefully for signs of overhydration, uremic complaints and malnutrition. Appropriate therapy changes might be considered (grade C)\textsuperscript{17}. Elizabeth Oei noticed that \( \text{Kt/V} \) targets >1.7 are based on studies that included very few elderly patients (>80 yrs-old). Escalate PD dose may be counterproductive in elderly and can increase technique failure\textsuperscript{84}.

Both \( \text{Kt/V} \) urea and creatinine clearance are useful but limited tool of adequacy quantifying only small solute removal and neglecting medium molecules and uremic toxins removal. However, creatinine peritoneal clearance is particularly useful to take into account in APD patients and slower transporters. In those patients, “adequate” \( \text{Kt/V} \) urea might be achieved but a slower transport of creatinine or phosphorus compromises its removal. By measuring creatinine peritoneal clearance, which correlates with phosphate clearance, several optimization steps such as increasing dwell times or adjusting number of cycles, for example, can be taken.

It must be highlighted, however, that adequacy of dialysis should be interpreted clinically (clinical and laboratory results, hydration status, energy level, anemia control, electrolytes and acid-base balance, blood pressure control) rather than by targeting only solute and fluid removal.

During the monthly evaluation of PD patients, nutritional status should be estimated. Serum albumin should be monitored, and when obtaining 24-hour total solute clearances, dietary protein intake estimations (DPI; such as nPNA) should be measured\textsuperscript{79}. Even more, serum albumin must be viewed in the patient context (peritoneal membrane transport type, total solute clearance, volume status, comorbid diseases and any inflammatory state)\textsuperscript{79}. Several investigators proposed that DPI should be in the 0.9 to 1.1 g/Kg/day range\textsuperscript{85,86}. When considering DPI targets however, it should be taken into account that level of evidence is limited and targets were extrapolated from predialysis populations. In dialysis, catabolism rate and metabolic demand is variable, so patients and modality variables confound PNA. More than PNA, also body composition (BIA) variables such as body cell mass or lean body mass and fat mass would be preferable to evaluate nutritional status. Many PD patients supposedly with malnutrition due to PNI < 1.1 g/Kg/day actually maintain age adjusted lean body mass. It might also be questionable if same targets should be applied to elderly patients.

Also, it is essential to emphasize the frequency of solute clearance and the importance of renal residual function.

1. **Frequency of solute clearance (renal and peritoneal) estimation**

Both residual renal and peritoneal dialysis small solute clearance should be evaluated at least every 6 months, or even more often if they are dependent on residual renal function. The urea and/or creatinine clearance can be used indistinctly, but should be interpreted within their limits (grade 1C)\textsuperscript{20}. The CSN guidelines proposed a measurement of total \( \text{Kt/V} \) 4-6 weeks after initiation of PD and thereafter it should be repeated whenever there is an unexplained change in the patient’s clinical status or a problem with ultrafiltration (opinion)\textsuperscript{19}. The Portuguese Good Practice Manual (PGPM) in Chronic Dialysis solutes clearance recommends weekly \( \text{Kt/V} \) evaluation every 4 months\textsuperscript{80}. It should be noted that all measurements of peritoneal solute clearance should be obtained when the patient is clinically stable and at least one month after resolution of an episode of peritonitis\textsuperscript{79}.

2. **Residual renal function**

Urine volume higher than 100 ml/day is considered significant. A mean of 24-hour urine urea clearance and urine creatinine clearance express RRF (grade D)\textsuperscript{79}.

The ISPD guidelines recommend monitoring RRF every 1–2 months if practicable, but no less than every 4–6 months, for patients that rely significantly in that component of the total small solute clearance (grade C)\textsuperscript{17}. The CSN guidelines indicate that RRF should be measured every 3–6 months in patients with peritoneal \( \text{Kt/V} <1.7 \) weekly and together with \( \text{Kt/V} \) when clinically indicated in all other patients (\( \text{Kt/V} \geq 1.7 \); grade D)\textsuperscript{19}. Studies of the adequacy of PD, measured by \( \text{Kt/V} \text{urea} \) and \( \text{Ccr} \), have shown that in the presence of RRF outcome is driven only by the kidney component(87-90).

### Guidelines on Nutrition

When nutrition is discussed, there are two opposite situations that require attention: sarcopenic-obesity and protein-energy wasting (PEW).

In 2008, the International Society of Renal Nutrition and Metabolism (ISRNRM) defined PEW as a state of decreased protein and energy body stores\textsuperscript{91}. PEW has been associated with major adverse clinical outcomes, increased rates of hospitalization and death\textsuperscript{92}. Prevalence of PEW is variable (18-75%)\textsuperscript{91}, and it is not clear if PD patients are more affected than hemodialysis patients. Some studies account serum albumin as a marker of PEW in PD patients, overestimating its prevalence in PD\textsuperscript{94}. Serum albumin in dialysis patients is related
to hydration status and inflammation and reflects loss of somatic protein only at late stage of PEW. Additionally, in PD patients a low albumin value may signify a greater loss of this protein without greater PEW risk.

The other aspect of nutrition is sarcopenic-obesity. Although this spectrum of nutrition is often neglected, including by the existing guidelines, some studies suggest that overweight is a more relevant problem than PEW in PD. Obesity is not correlated with peritoneal transport or glucose absorption but is clearly associated with insulin resistance. Some authors suggest that cumulative exposure to glucose solutions used in PD might lead to systemic hyperglycemia, insulin resistance and obesity, which can contribute to increased cardiovascular risk.

Here, we will review four essential aspects of nutrition recommendations related to PEW, since sarcopenic-obesity is neglected by existing guidelines.

1. Nutritional counseling

It is advisable that all dialysis patients should receive nutritional counseling (ERBP: Evidence C; KDOQI: Opinion)(97, 98). In 2000, KDOQI recommendations suggested following an individualized plan before or during the early phase of dialysis therapy, to be updated at least every three to four months. There are no more recent guidelines regarding this matter.

2. Nutritional assessment

In terms of nutritional assessment there are two important questions that need to be addressed: when and how it is to be carried out?

The most recent guidelines in this respect are from the ISPD and recommend that a nutritional assessment of PD patients be made during the period of six to eight weeks after initiation of the technique and then regularly, at least every four to six months (ungraded). There is no tool that can, of itself, reliably assess nutritional status, which is why the use of a combination of various tools is recommended (KDOQI: opinion). In 2005, ERBP guidelines acknowledged that serum albumin alone was not a clinically useful measure of nutritional assessment in PD patients (Evidence B). These guidelines recommend the use of subjective global assessment, protein intake (assessed from the protein equivalent of total nitrogen appearance, nPNA, or by dietary recall) and an assessment of protein nutrition (Evidence C) to assess nutritional patient status. The diagnosis of PEW was proposed by the ISRNM based on serum chemistry, body and muscle mass and dietary intake.

More recently, bioimpedance has been used in several studies to assess patient body composition and has shown some relationship with patient survival. However, over the last ten years, nutrition guidelines in dialysis patients have not been reviewed and this tool has not yet been integrated into the international guidelines.

3. PEW prevention

PEW prevention includes adequate protein and energy intake. The most recent recommendations date from 2013 (ISRNM Consensus) and recommend a protein intake higher than 1.2g/kg/day (higher than 1.5g/kg/day during peritonitis episodes), more than 50% of which must be of high biological value, and an energetic intake of 30-35 kcal/kg/day (including kcal from dialysate), both based on ideal body weight. For the sedentary elderly, the recommended energy intake, based on physical activity level, is only 30 kcal/kg/day.

ISRNM Consensus also advocates a minimum dialysis dose for maintaining adequate intake and preserving nutritional status. However, it should be noted that increasing dialysis dose beyond the recommended did not show efficacy in improving nutritional status. The same document proposes additional measures for PEW prevention, including metabolic acidosis correction until the level of bicarbonate is higher than 22 (with increased dialysis dose and/or oral bicarbonate), and the reduction of systemic inflammation through early treatment of inflammatory conditions and adequate volume control.

4. PEW treatment

Before any therapeutic attitude, detection and correction of reversible causes are mandatory (ERBP: Evidence C). Exclusion of any causes other than those related to dialysis technique (dialysis inadequacy and metabolic acidosis), namely, psychiatric, socioeconomic and other medical causes (gastroparesis, malabsorption, early satiety, inflammation) are warranted.

Treatment of PEW is accomplished with nutritional support. Ideally, oral diet may be reinforced with energy and protein supplements. This intake should be carried out two to three times a day, after meals, for at least three to twelve months, to provide an additional energy intake of 7-10 Kcal/kg/day and protein of 0.3-0.4g/kg/day. For patients who are unable to tolerate nutritional supplementation by mouth, tube feeding should be considered.

Intraperitoneal amino acid solutions have been described as an alternative to treatment of malnutrition in PD patients. Recommendations are contradictory, although the most recent consensus is in favor of their use. If intraperitoneal amino acid solutions are used, more than one daily exchange is not recommended (ISPD: grade A) and monitoring of acidosis and uremia (ISPD: grade B) is required. Although this measure appears to have little impact in PEW treatment, it may be an important weapon, along with use of icodextrin solutions and preservation of residual renal function, as a glucose-sparing strategy in obese patients. Finally, the use of anabolic steroids (nandrolone decanoate 100mg intramuscular injection weekly) for up to six months (ISPD: grade B) or the appetite stimulant megestrol acetate (ISPD: grade D) should be considered to improve nutritional condition.

Guidelines on Cardiovascular and metabolic risk

Adult peritoneal dialysis patients present high cardiovascular morbidity and mortality, since coronary artery disease, left ventricular hypertrophy, heart failure, atrial fibrillation, cerebrovascular disease and peripheral artery disease are highly prevalent in this population. Thus, it is essential to identify interventions that can lead to reduce cardiovascular...
mortality and enhanced survival amongst these patients. Currently, the available evidence is not enough to determine the optimal approach in some areas, highlighting the need for further studies.

1. Coronary artery disease

The diagnosis of acute coronary syndrome (ACS) requires the determination of biomarkers of cardiac injury, such as troponin I and T. Its reference range is difficult to define in the general population and even more so in dialysis patients, since they are frequently elevated even in the absence of an acute coronary event\textsuperscript{102,103}. The underlying pathophysiological mechanism is not entirely understood; several hypotheses including the influence of different laboratory assays\textsuperscript{104,105} and residual renal function\textsuperscript{106,107} have been proposed, with studies available showing conflicting results. Nonetheless, it has been noted that elevated cardiac biomarkers correlate with myocardial leak\textsuperscript{102} – even after adjusting for residual renal function and the type of deputative technic used – which implies underlying cardiac disease\textsuperscript{104,108}. Troponin elevation in these patients may indicate variable cardiac disease and not necessarily acute ischemic events\textsuperscript{103,105,109}.

A single elevated value has little or no diagnostic utility; however, it may be of potential interest for cardiovascular risk stratification\textsuperscript{105,109,110}. Studies in PD suggest an association between elevated troponin T and LVH, global and cardiovascular mortality\textsuperscript{105}. Elevated troponin T predicts long-term mortality, cardiovascular events and cardiovascular mortality\textsuperscript{103,104,110-112}. There is insufficient data to recommend its routine use; nonetheless, in case of incidental detection of raised troponin, these patients may benefit from additional investigation to detect silent cardiac disease, such as LVH, CAD or systolic dysfunction. Conversely, high troponin detected in serial measurements in the appropriated clinical setting establishes the diagnosis of ACS – the difficulty in this subset of patients is to define the range\textsuperscript{113}. Therefore, in the presence of acute symptoms along with electrocardiographic changes or any other clinical alteration suggestive of acute myocardial ischemia, a serial measurement of cardiac biomarkers should be undertaken to evaluate a possible ACS. A rise in troponin level > 20%, with at least one value above 99th percentile, within 4-9h is diagnostic\textsuperscript{114,115}.

Cardiovascular disease in end-stage renal disease (ESRD) is underdiagnosed and undertreated, since its signs and symptoms are often subtle\textsuperscript{116,117}. Routine screening has been considered in this population; however there is not enough evidence to support it. A careful history and physical examination are sufficient to identify patients with high pretest probability of having significant cardiac disease, without potential adverse effects or additional costs\textsuperscript{114,117}. In renal transplant candidates, further investigation with non-invasive stress tests should be carried out if there are three or more of the following risk factors: diabetes, previous history of cardiovascular disease, more than one year on dialysis, LVH, age above 60 years, smoking, hypertension and dyslipidemia\textsuperscript{114,117}. The above criteria were based upon the Lisbon Conference Report 2007 recommendations and represent an alternative to the ones defined by the American Heart Association and the American College of Cardiology for the general population, with higher sensitivity and specificity in chronic kidney disease (CKD)\textsuperscript{118}.

After the diagnosis, patients with CKD are less likely to be prescribed anti-platelet agents – only about 27-49%\textsuperscript{118,119,120}. Studies in PD are lacking; however observational studies in hemodialysis (HD) have shown that only about half the patients (51%) with indication were on acetylsalicylic acid for primary and secondary prevention of CAD, and amongst the ones not taking it, 53% had clear indication without identified contraindication\textsuperscript{121}. A meta-analysis that included 17 studies with ESRD patients concluded that anti-platelet agents reduce the risk of acute myocardial infarction (AMI)\textsuperscript{122}. Thus, in the absence of an increased bleeding risk, PD patients should be treated the same way as the general population\textsuperscript{114}.

Current guidelines suggest that dyslipidemia management in PD patients should follow the KDIGO recommendations\textsuperscript{78}. An initial evaluation of lipid profile should be performed; however monitoring its levels is not required. If a patient is already on pharmacological therapy, then it should be maintained; otherwise, it should not be initiated\textsuperscript{123}.

2. Left ventricular hypertrophy and dysfunction |Heart failure

LVH, systolic dysfunction and heart failure are highly prevalent in PD patients – reported in over 90, 16 and 39%, respectively\textsuperscript{124}. It translates into high morbidity and mortality, since the presence of systolic dysfunction is associated with a higher risk of heart failure and sudden death, and they all predict mortality\textsuperscript{125, 126}. Hence, an echocardiogram should be performed when starting PD and whenever a clinical alteration is detected, to evaluate for LVH, dilatation, systolic and diastolic functions, as well as cardiac valvular abnormalities. In patients with significant systolic dysfunction, further investigation to exclude possible CAD is recommended\textsuperscript{114}.

Data regarding the use of several drugs frequently prescribed to the general population suggest they may also be beneficial in PD patients. The use of angiotensin converting enzyme inhibitors (ACEI), angiotensin II receptor blockers (ARB) and beta blockers (BB) should be considered in PD patients with LVH, dilated cardiomyopathy or systolic heart failure; when already receiving treatment with ACEI or ARB, consider adding a mineralocorticoid receptor antagonist (MRA)\textsuperscript{114}. Observational studies showed that ACEI/ARB utilization is associated with a reduction in cardiovascular events, and cardiovascular and all-cause mortality, even after adjusting for other risk factors and patient characteristics\textsuperscript{127,128}. Concerning the treatment with MRA, a randomized controlled trial (RCT) in PD showed that, when added to a ACEI or ARB, spironolactone significantly reduces the rate of progression in left ventricular mass index and improves ejection fraction for 24 months\textsuperscript{129}. Studies evaluating the influence of BB in LVH, systolic dysfunction and HF related outcomes in PD patients are lacking. However, in HD patients, its use improved left ventricular remodeling and functional class in patients with dilated cardiomyopathy sustained for a period of 24 months and showed significant benefit in survival, cardiovascular mortality, fatal AMI, stroke, HF related and all-cause hospitalizations\textsuperscript{130}.

The optimal hemoglobin target level when treating anemia and its prognosis in PD patients with HF remains elusive. RCTs in HD have failed to demonstrate greater regression of LVH and dilatation with higher values\textsuperscript{131, 132}. On the other hand, an observational study including PD patients found that a target below 11-12 g/dL was
associated with higher cardiovascular and global mortality. There is insufficient data to recommend a dissimilar approach and hemoglobin goals in patients with or without Hf.

3. Cerebrovascular disease

Screening for CVD in PD patients is not recommended; however, a carotid duplex ultrasonography should be performed in those presenting with a transient ischemic attack (TIA) or stroke, since it allows the identification of modifiable abnormalities with prognostic significance. The use of anti-platelet agents for stroke prevention in high-risk patients is well established in the general population. In patients with ESRD, the evidence of benefit is scanty, and its use significantly increases the risk of major bleeding. Therefore, these agents should not be prescribed for primary prevention. Most studies available regarding treatment with warfarin excluded dialysis patients. The remaining few including individuals with CKD have failed to demonstrate a reduction in the combined risk of ischemic and hemorrhagic stroke, with a significant increase in bleeding events. Recently, a retrospective observational study in PD evaluated warfarin use and its impact in ischemic stroke prevention in the presence of AF. Anti-coagulation was associated with less cerebrovascular events when compared with aspirin or no treatment, without an increased risk of intracranial hemorrhage. Giving the inconsistency of available results, its prescription should be individualized considering the increased risk of bleeding and uncertain effects on cerebrovascular outcomes. In the absence of clinical trials including this subset of patients, the use of new/direct oral anti-coagulants is not recommended for thromboembolic stroke prevention in PD with AF.

Potential benefits and complications of thrombolytic therapy have not been evaluated specifically in PD patients. Observational data in ESRD suggest similar risk of bleeding as in the general population; however, it is associated with adjusted higher in-hospital mortality, length of stay and in-hospital complications. Therefore, caution is necessary since it is not clear if benefits outweigh risks.

4. Peripheral artery disease

About 27-31% of all PD patients have PAD and, in those above 70 years old, its prevalence can be as high as 45%. PAD is independently associated with cardiovascular and overall mortality. Studies comparing routine screening vs. evaluation in the presence of clinical signs and symptoms are absent in dialysis patients; therefore, the guidelines recommend similar assessment and treatment as for the general population.

Generally, the diagnosis is made by an ankle-brachial pressure index (ABI) < 0.9. Although highly sensitive and specific for the general population (95 and 100% respectively), its performance has not been studied in CKD patients. Considering the high prevalence of vascular calcifications in this subset of patients, the toe-brachial index (TBI) has presented as an alternative, since smaller vessels are less likely to be affected. An ABI > 1.3 or a systolic blood pressure measured in the leg more than 20% the one evaluated in the arm suggest the presence of non-compressible vessels; and therefore, the ABI may be unreliable. A TBI (which is diagnostic if < 0.6) may be indicated in those cases. This tool has been validated for the diagnosis of PAD in PD; still studies concerning its sensitivity and specificity, clinical performance (vs. doppler or angiography), and predictive value for vascular events and complications remain to be carried out.

Even though no solid evidence exists in ESRD, supervised exercise therapy is recommended in the absence of critical disease. Anti-platelet therapy should be considered in PD patients according to the same indications accepted for the general population, always keeping in mind the possible augmented risk of bleeding. An observational study in PD suggests reduced amputations with multidisciplinary foot care – regular foot evaluation, podiatrist treatment and awareness of home foot care.

5. Cardiac arrhythmias

AF is highly prevalent in dialysis patients (between 12.5-27% in HD) with a higher frequency than in the general population. It is also associated with higher mortality. Thus, a 12-lead electrocardiogram should be performed in all patients starting PD and then annually, to screen for cardiac arrhythmias including AF. As mentioned previously, hypocoagulation in this subset of patients should be individualized given the inconsistent results of available studies.

6. Sudden cardiac death

Sudden cardiac death (SCD) accounts for about one-fourth of all deaths in PD. It has been associated with raised troponins and N-terminal pro-brain natriuretic peptide. The presence of heart failure and systolic dysfunction are predictive factors of its occurrence, and a previous episode of tachyarrhythmic cardiac arrest is associated with increased risk of SCD in HD patients. Therefore, patients with low ejection fraction, elevated troponins and N-terminal pro-brain natriuretic peptide, and that have survived a previous tachyarrhythmic cardiac arrest should be considered as being at high risk of SCD.

There are no studies regarding therapeutic interventions in PD, or RCT with antiarrhythmics for the prevention of SCD, or evaluating the efficacy of implantable cardioverter (ICD) in primary prevention in patients on dialysis. Observational studies in HD suggest a reduced number of events when using BB in patients with CAD and a benefit of ICD for secondary prevention of SCD. Hence, current expert opinion is that BB should be consider for primary prevention of SCD in high risk PD patients, and ICD for secondary prevention in patients with a previous episode of cardiac arrest as a consequence of a malignant ventricular arrhythmia (except those occurring in the first 48h after AMI).

CONCLUSIONS

Solutes and fluid removal are key points in PD patients’ treatment. Both, when optimized, are of utmost importance for maintaining patients asymptomatic and to extend in time PD treatment. RRF is as important as dialysis dose. In fact, RRF is one of the most important factors that predict survival in PD patients, and its preservation is fundamental in the follow-up of these patients. Cardiovascular events are frequent and primary prevention must be considered in PD patients in line with the same indications accepted for the general population.

Disclosure of potential conflicts of interest: none declared.
References


Peritoneal Dialysis Adequacy Work G.


Correspondence to: ana carina ferreira, md Rua da Beneficência, nº 8; 1069-166, Lisboa, Portugal.

E-mail: a.carina.carina.ferreira@gmail.com